Associations between nocturnal urinary 6-sulfatoxymelatonin, obstructive sleep apnea severity and glycemic control in type 2 diabetes

References

• Aronsohn RS, Whitmore H, Van Cauter E, Tasali E. (2010). Impact of untreated obstructive sleep apnea on glucose control in type 2 diabetes. Am J Respir Crit Care Med. 181:507–13.
   PubMed Web of Science ®Google Scholar
• Bertuglia S, Reiter RJ. (2009). Melatonin reduces microvascular damage and insulin resistance in hamsters due to chronic intermittent hypoxia. J Pineal Res. 46:307–13.
   PubMed Web of Science ®Google Scholar
• Bonnefond A, Clement N, Fawcett K, et al. (2012). Rare MTNR1B variants impairing melatonin receptor 1B function contribute to type 2 diabetes. Nat Genet. 44:297–301.
   PubMed Web of Science ®Google Scholar
• Brzecka A, Piesiak P, Zareba-Bogdal E, et al. (2001). Rhythm of melatonin excretion in obstructive sleep apnea syndrome. Pneumonol Alergol Pol. 69:650–54.
   PubMedGoogle Scholar
• Brzezinski A. (1997). Melatonin in humans. N Engl J Med. 336:186–95.
   PubMed Web of Science ®Google Scholar
• Chen W, Cao H, Lu QY, et al. (2014.) Urinary 6-sulfatoxymelatonin level in diabetic retinopathy patients with type 2 diabetes. Int J Clin Exp Pathol. 7:4317–22.
   PubMed Web of Science ®Google Scholar
• Didelez V, Sheehan N. (2007). Mendelian randomization as an instrumental variable approach to causal inference. Stat Methods Med Res. 16:309–30.
   PubMed Web of Science ®Google Scholar
• Garfinkel D, Zorin M, Wainstein J, et al. (2011). Efficacy and safety of prolonged-release melatonin in insomnia patients with diabetes: A randomized, double-blind, crossover study. Diabetes Metab Syndr Obes. 4:307–13.
   PubMedGoogle Scholar
• Haimov I, Laudon M, Zisapel N, et al. (1994). Sleep disorders and melatonin rhythms in elderly people. BMJ. 309:167.
   PubMed Web of Science ®Google Scholar
• Hernandez C, Abreu J, Abreu P, et al. (2007). Nocturnal melatonin plasma levels in patients with OSAS: the effect of CPAP. Eur Respir J. 30:496–00.
   PubMed Web of Science ®Google Scholar
• Hikichi T, Tateda N, Miura T. (2011). Alteration of melatonin secretion in patients with type 2 diabetes and proliferative diabetic retinopathy. Clin Ophthalmol. 5:655–60.
   PubMedGoogle Scholar
• Hung MW, Kravtsov GM, Lau CF, et al. (2013). Melatonin ameliorates endothelial dysfunction, vascular inflammation, and systemic hypertension in rats with chronic intermittent hypoxia. J Pineal Res. 55:247–56.
   PubMed Web of Science ®Google Scholar
• Imai K, Keele L, Tingley D. (2010). A general approach to causal mediation analysis. Psychol Methods. 15:309–34.
   PubMed Web of Science ®Google Scholar
• Kellner M, Yassouridis A, Manz B, et al. (1997). Corticotropin-releasing hormone inhibits melatonin secretion in healthy volunteers–a potential link to low-melatonin syndrome in depression? Neuroendocrinology. 65:284–90.
   PubMed Web of Science ®Google Scholar
• Kozirog M, Poliwczak AR, Duchnowicz P, et al. (2011). Melatonin treatment improves blood pressure, lipid profile, and parameters of oxidative stress in patients with metabolic syndrome. J Pineal Res. 50:261–66.
   PubMed Web of Science ®Google Scholar
• Lavie L. (2015). Oxidative stress in obstructive sleep apnea and intermittent hypoxia–revisited–the bad ugly and good: Implications to the heart and brain. Sleep Med Rev. 20:27–45.
   PubMed Web of Science ®Google Scholar
• Leproult R, Holmback U, Van Cauter E. (2014). Circadian misalignment augments markers of insulin resistance and inflammation, independently of sleep loss. Diabetes. 63:1860–69.
   PubMed Web of Science ®Google Scholar
• MacKinnon DP, Fairchild AJ, Fritz MS. (2007). Mediation analysis. Annu Rev Psychol. 58:593–14.
   PubMed Web of Science ®Google Scholar
• MacKinnon DP, Lockwood CM, Hoffman JM, et al. (2002). A comparison of methods to test mediation and other intervening variable effects. Psychol Methods. 7:83–04.
   PubMed Web of Science ®Google Scholar
• Mantele S, Otway DT, Middleton B, et al. (2012). Daily rhythms of plasma melatonin, but not plasma leptin or leptin mRNA, vary between lean, obese and type 2 diabetic men. PLoS One. 7:e37123.
   PubMed Web of Science ®Google Scholar
• Mauriz JL, Collado PS, Veneroso C, et al. (2013). A review of the molecular aspects of melatonin’s anti-inflammatory actions: Recent insights and new perspectives. J Pineal Res. 54:1–14.
   PubMed Web of Science ®Google Scholar
• McMullan CJ, Schernhammer ES, Rimm EB, et al. (2013). Melatonin secretion and the incidence of type 2 diabetes. JAMA. 309:1388–96.
   PubMed Web of Science ®Google Scholar
• Pallayova M, Banerjee D, Taheri S. (2014). Novel insights into metabolic sequelae of obstructive sleep apnoea: A link between hypoxic stress and chronic diabetes complications. Diabetes Res Clin Pract. 104:197–05.
   PubMed Web of Science ®Google Scholar
• Papaioannou I, Twigg GL, Kemp M, et al. (2012). Melatonin concentration as a marker of the circadian phase in patients with obstructive sleep apnoea. Sleep Med. 13:167–71.
   PubMed Web of Science ®Google Scholar
• Peschke E, Frese T, Chankiewitz E, et al. (2006). Diabetic Goto Kakizaki rats as well as type 2 diabetic patients show a decreased diurnal serum melatonin level and an increased pancreatic melatonin-receptor status. J Pineal Res. 40:135–43.
   PubMed Web of Science ®Google Scholar
• Peschke E, Muhlbauer E. (2010). New evidence for a role of melatonin in glucose regulation. Best Pract Res Clin Endocrinol Metab. 24:829–41.
   PubMed Web of Science ®Google Scholar
• Pillai A, Warren G, Gunathilake W, Idris I. (2011). Effects of sleep apnea severity on glycemic control in patients with type 2 diabetes prior to continuous positive airway pressure treatment. Diabetes Technol Ther. 13:945–9.
   PubMed Web of Science ®Google Scholar
• Preacher KJ, Hayes AF. (2008). Asymptotic and resampling strategies for assessing and comparing indirect effects in multiple mediator models. Behav Res Methods. 40:879–91.
   PubMed Web of Science ®Google Scholar
• Reutrakul S, Van Cauter E. (2014). Interactions between sleep, circadian function, and glucose metabolism: implications for risk and severity of diabetes. Ann NY Acad Sci. 1311:151–73.
   PubMed Web of Science ®Google Scholar
• Rubio-Sastre P, Scheer FA, Gomez-Abellan P, et al. (2014). Acute melatonin administration in humans impairs glucose tolerance in both the morning and evening. Sleep. 37:1715–19.
   PubMed Web of Science ®Google Scholar
• Saksvik-Lehouillier I, Harrison SL, Marshall LM, et al. (2015). Association of Urinary 6-Sulfatoxymelatonin (aMT6s) Levels and Objective and Subjective Sleep Measures in Older Men: The MrOS Sleep Study. J Gerontol A Biol Sci Med Sci. 70:1569–77.
   PubMed Web of Science ®Google Scholar
• Scheer FA, Hilton MF, Mantzoros CS, Shea SA. (2009). Adverse metabolic and cardiovascular consequences of circadian misalignment. Proc Natl Acad Sci USA. 106:4453–8.
   PubMed Web of Science ®Google Scholar
• Sitasuwan T, Bussaratid S, Ruttanaumpawan P, Chotinaiwattarakul W. (2014). Reliability and validity of the Thai version of the Pittsburgh Sleep Quality Index. J Med Assoc Thai. 97 Suppl 3:S57–67.
   PubMedGoogle Scholar
• Somers VK, White DP, Amin R, et al. (2008). Sleep apnea and cardiovascular disease: an American Heart Association/american College Of Cardiology Foundation Scientific Statement from the American Heart Association Council for High Blood Pressure Research Professional Education Committee, Council on Clinical Cardiology, Stroke Council, and Council On Cardiovascular Nursing. In collaboration with the National Heart, Lung, and Blood Institute National Center on Sleep Disorders Research (National Institutes of Health). Circulation. 118:1080–11.
   Google Scholar
• Sparso T, Bonnefond A, Andersson E, et al. (2009). G-allele of intronic rs10830963 in MTNR1B confers increased risk of impaired fasting glycemia and type 2 diabetes through an impaired glucose-stimulated insulin release: Studies involving 19,605 Europeans. Diabetes. 58:1450–56.
   PubMed Web of Science ®Google Scholar
• Srinivasan V, Smits M, Spence W, Lowe AD, et al. (2006). Melatonin in mood disorders. World J Biol Psychiatry. 7:138–51.
   PubMed Web of Science ®Google Scholar
• Staiger D, Stock JH. (1997). Instrumental variables with weak instrument. Econometrica. 65:557–86.
   Web of Science ®Google Scholar
• Trangkasombat U, Larpboonsarp V, Havanond P. (1997). CES-D as a screen for depression in adolescents. Journal of the Psychiatric Association of Thailand. 42:2–13.
   Google Scholar
• Tuomi T, Nagorny CL, Singh P, et al. (2016). Increased Melatonin Signaling Is a Risk Factor for Type 2 Diabetes. Cell Metab. 23:1067–77.
   PubMed Web of Science ®Google Scholar
• Ulfberg J, Micic S, Strom J. (1998). Afternoon serum-melatonin in sleep disordered breathing. J Intern Med. 244:163–8.
   PubMed Web of Science ®Google Scholar
• Vgontzas AN, Pejovic S, Zoumakis E, et al. (2007). Hypothalamic-pituitary-adrenal axis activity in obese men with and without sleep apnea: Effects of continuous positive airway pressure therapy. J Clin Endocrinol Metab. 92:4199–207.
   PubMed Web of Science ®Google Scholar
• Wikner J, Svanborg E, Wetterberg L, Rojdmark S. (1997). Melatonin secretion and excretion in patients with obstructive sleep apnea syndrome. Sleep. 20:1002–7.
   PubMed Web of Science ®Google Scholar
• Zirlik S, Hildner KM, Targosz A, et al. (2013). Melatonin and omentin: influence factors in the obstructive sleep apnoea syndrome? J Physiol Pharmacol. 64:353–60.
   PubMed Web of Science ®Google Scholar
• Zou D, Grote L, Peker Y, et al. (2006). Validation a portable monitoring device for sleep apnea diagnosis in a population based cohort using synchronized home polysomnography. Sleep. 29:367–74.
   PubMed Web of Science ®Google Scholar